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DISCUSSION
Dr Daniel Clair (New York, NY). I’d like to congratulate Dr
Lal on an excellent presentation and the authors on a well-written
paper addressing a topic that I believe most surgeons think has
receive limited attention by nonsurgeons performing this proce-
dure. I’d also like to thank the authors for supplying me with a copy
of their manuscript for review.
I have several questions for the authors regarding their study.
In terms of classification of the lesions, degree of stenosis with
duplex ultrasound, are there any changes in specific duplex criteria
that were utilized in patients evaluated with ultrasound in the
poststenting situation?
It is clear that data generated from duplex evaluations have
been confirmed in patients with primary carotid stenosis; however,
the stents clearly alter the hemodynamics of the bifurcation and
may affect classification of duplex ultrasound data in terms of the
degree of stenosis. Were there any other evaluations done of these
patients to confirm the degree of stenosis on the poststenting
duplex evaluations?
Another question I have relates to standard errors (SEs) that
were missing from the life table analysis at the 60-month time
point. It was difficult with a mean follow-up of 18 months to get a
sense of how meaningful the data at 60 months would be for this
patient population without some form of SE bars on the life table
analysis graphs.
Another question I have relates to information gained from
this study in terms of the technique of carotid artery stenting.
There are a limited number of patients who went on to have
reintervention, and I’m sure those patients have had review of their
initial angiographic data. Since the occurrences usually occurred at
the stent end points, were there any abnormalities at the stent end
points at initial stent placement? Specifically, were there problems
with the stent-to-arterial wall coapctation in these regions, in-
creased tortuosity, especially at the distal end points, or any other
issues which may have altered the authors’ techniques of carotid
stenting in these patients?
Dr Brajesh K. Lal. In terms of changes in duplex ultrasound
diagnostic criteria, the patients were scanned using the same crite-
ria in our ICAVAL-approved laboratory. We have noticed changes
in velocities in some of our patients and, in fact, are going to report
a detailed analysis of this at the upcoming national meeting (Vas-
cular 2003). We are revising our velocity criteria; however, our
follow-up protocol also incorporates detailed B-mode scans in any
patient identified as having restenosis on the basis of velocity
criteria. Only then is the patient categorized as having a significant
in-stent restenosis.
All the graphs clearly indicate the standard errors at the
bottom. All the data reported at 60 months for 80% in-stent
restenosis and at 48 months for the 60% and 40% in-stent resteno-
ses are with standard errors less than 10. So they’re all significant in
that respect.
As far as the technique for reintervention is concerned, I agree
with you: little has been written about it because very few of the
physicians who have published on carotid stenting in large num-
bers have analyzed their incidence of in-stent restenosis, using life
table analysis.
We chose to report our in-stent restenoses and discuss the
technique and approach that we have used to try and open up a
discussion on this fact. One of our patients, as we have described,
went on to occlude after restenting. Another required 3 subse-
quent interventions to maintain arterial patency and is currently at
40% to 59% in-stent restenosis. So when do we call a halt and
operate on these patients? These are issue that still need to be
studied, reported, and debated.
Dr Ali F. AbuRahma (Charleston, WV). I’d like to empha-
size a point, which I hope the author includes in the paper prior to
submitting it to the Journal of Vascular Surgery, since the study
will be quoted by many of our nonsurgical colleagues in North
America. As the author indicated, a significant number of his
patients have stenoses of80%; as a matter of fact, you have a total
of 14 patients with stenoses of 40% to 60% and 60% to 80% in this
group. Can you imagine if the follow-up were longer? Some of
these patients could have progressed to80%. Therefore, perhaps
the paper should emphasize the fact that even though the numbers
of patients with stenoses of80% was somewhat low at 18 months,
this number could increase if the follow-up was longer.
Dr Lal. We agree on the importance of long-term follow-up.
We have emphasized that there are several patients with in-stent
restenosis who have not approached the hemodynamically signifi-
cant (80%) limit That is why this study incorporated reporting on
the 60% and the 40% in-stent restenosis rates. These patients do
require longer follow-up and there’s more to the story that may
evolve later. Most of the publications on in-stent restenosis after
CAS are on short-term follow-ups, with reporting of 80% resteno-
sis. The current study identifies the entire range of restenoses.
Dr Bruce Perler (Baltimore, Md). My question relates to the
obvious dramatic improvement in outcome in your center. As I
recall Dr Hobson’s earlier report, which you cited, at 1 year the rate
of 80% restenosis was 8%. And now you’re telling us that at 5
years the rate of 80% restenosis is about 6.5%. So I wonder whether
that initial cohort of 50 patients was included in this series of 100
cases. And whether it was or wasn’t, might you speculate on why
the long-term durability has gotten so much better? I could see
periprocedural morbidity improving with experience, but I’m not
sure I understand why the durability would improve. Is there a
change in your selection of stent, change in technique, or some
other cause?
I ask because, as the other speakers have said, there clearly are
other series reporting much more dramatic rates of restenosis, such
as CAVATAS, where at 1 year a severe restenosis or occlusion
occurred in, I believe, 23% of patients, and other series support
that. So why are your results becoming so much more durable?
How have you changed what you’re doing?
Dr Lal. To answer your last question first, in CAVATAS the
majority of patients were treated with angioplasty alone, and
carotid stenting was a rescue procedure that occurred in only 25%
of the patients. That may explain the high restenosis rates in that
study. After the four restenoses noted in our first 50 patients, there
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has been only one other 80% restenosis in the 70-odd patients who
have been treated after that time. We looked into the subset. In the
paper we have, indeed, reported log-rank comparisons between
survival curves of the Wallstents that we were using originally and
the nitinol stents that we are using now, as well as whether there
was a difference between post-CEA restenosis patients, whom we
were treating initially, and primary high-risk patients with symp-
toms. There were no significant differences; however, the numbers
were too low to make a definitive determination. We suspect it has
to do with the type of stent we have been using.
Dr Luis A. Queral (Baltimore, Md). I’m wondering if you
can comment on whether it’s justified to put patients with recur-
rent artery stenoses with primary disease in the same group, inas-
much as the pathogenesis seems to be somewhat different. I also
wonder whether the type of endarterectomy performed on 65% of
these patients influenced the recurrence rate, whether it was
patched or not patched, a reversion. And I know that’s an old
question in vascular surgery, but it has an impact here since that’s
the majority of your patients. And finally, can you relate the
recurrence rate to the location of this restenosis? It seems to me
that it might be a different thing to have a recurrent stenosis in the
common carotid proximal to the previously treated lesion versus
one in the internal carotid artery above the area of surgery.
Dr Lal. I think that’s an excellent question. Restenotic lesions
within a 36-month period after CEA are usually secondary to
intimal hyperplasia. And several authors have speculated that a
stent in such a lesion may induce higher rates of in-stent restenosis.
We compared the in-stent restenosis rates of our post-CEA
restenosis patients with our primary lesion patients and haven’t
noticed any difference. It may just mean that the number of
patients that we have in our group right now is too low to identify
that difference. And that’s probably the best that can be said right
now in answer to your question. Unfortunately, some of the
publications with large numbers of patients have not followed their
patients beyond 6 months.
Dr Linda Harris (Buffalo, NY). Have you looked at the
subset of patients with the primary atherosclerotic disease, which is
a different entity than restenotic lesions? What is your follow-up on
those individuals, and on the basis of that, can we say anything
about stenosis in those individuals with carotid stenting or not?
Dr Lal. The mean follow-up for our primary patients is
approximately 16 months, so it’s not very different from the mean
follow-up of our entire cohort. And again, the in-stent restenosis
rates between our primary and our restenotic patient groups are
not significantly different as yet. Two of our patients out of the
hemodynamically significant five patients had primary lesions and
three had restenotic lesions.
INVITED COMMENTARY
Kenneth Ouriel, MD
The article by Lal and colleagues represents an important
contribution to the accumulating body of knowledge upon which
clinical decisions concerning carotid angioplasty and stenting will
be made. Uniquely, this study defines the long-term incidence of
in-stent restenosis and its clinical relevance. The authors concluded
that restenosis after carotid stenting is both an infrequent event
(6% at 5 years) and one rarely associated with neurologic sequelae
(0/5 restenoses). For sure, Lal’s study has limitations. The duplex
criteria for restenotic lesions appear to be validated for primary,
nonstented carotid arteries and not for either recurrent lesions after
endarterectomy or for in-stent restenoses. The number of evalu-
able patients at 5 years is small (four patients at the 60-month time
point), the study population is skewed toward patients with reste-
nosis after carotid endarterectomy, and a majority of patients were
treated with a stent that many would consider outmoded. While
subgroup analyses failed to identify relationships between these
variables and outcome, the statistical power of these analyses was
low. Importantly, the infrequent occurrence of restensosis (5 of
122 cases) accounts for much uncertainty in the estimate of reste-
nosis-associated neurologic events. The observed frequency of
zero events in five restenotic patients does not exclude a true rate of
symptoms as high as 45% (95% confidence interval, 0%-45%).
These limitations aside, Lal’s study represents yet another
piece of the carotid stenting puzzle, providing data on the dura-
bility of the procedure. Restenosis after carotid stenting does not
appear to occur with the frequency observed in smaller vessels such
as the coronary arteries. Rather, the rate of restenosis after carotid
stenting appears analogous to that following carotid endarterec-
tomy; restenosis occurs infrequently and when it does, it often
develops silently and without symptoms. Taken in concert with the
accumulating body of evidence on the short-term safety of stent-
ing, the restenosis data add to the realization that percutaneous
carotid interventions are often reasonable alternatives to standard
carotid endarterectomy. Although this is a finding that few sur-
geons would have predicted, failure to embrace this evolving
technology risks exclusion from participation in the care of patients
with carotid disease. On the other hand, involvement in the
ongoing investigations of carotid stenting will, in the words of
Winston Churchill, ensure that “history will look favorably upon
us, for we will write it.”
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